Durvalumab and Tremelimumab as First Line Treatment in Participants with Advanced Hepatocellular Carcinoma (HCC) - SIERRA

Study identifier:D419CR00030

ClinicalTrials.gov identifier:NCT05883644

EudraCT identifier:N/A

CTIS identifier:2022-502012-37-00

Recruiting

Official Title

A Phase IIIb Single Arm, Open-label, Multicentre Study of Durvalumab and Tremelimumab as First Line Treatment in Participants with Advanced Hepatocellular Carcinoma (SIERRA)

Medical condition

Advanced Hepatocellular Carcinoma

Phase

Phase 3

Healthy volunteers

No

Study drug

Durvalumab, Tremelimumab

Sex

All

Estimated Enrollment

140

Study type

Interventional

Age

18 Years - 130 Years

Date

Study Start Date: 27 Jun 2023
Estimated Primary Completion Date: 30 Jun 2025
Estimated Study Completion Date: 30 Dec 2025

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Mar 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria